Hypermutation as a Potential Predictive Biomarker of Immunotherapy Efficacy in High-Grade Gliomas: A Broken Dream?

References

• Louis DN , PerryA , ReifenbergerGet al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol.131(6), 803–820 (2016).
   PubMed Web of Science ®Google Scholar
• Brandes AA , BartolottiM , TosoniAet al. Nitrosoureas in the management of malignant gliomas. Curr. Neurol. Neurosci. Rep.16(2), 13 (2016).
   PubMed Web of Science ®Google Scholar
• Lombardi G , DeSalvo GL , BrandesAAet al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol.20(1), 110–119 (2019).
   PubMed Web of Science ®Google Scholar
• Brandes AA , TosoniA , FranceschiEet al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother. Pharmacol.64(4), 69–75 (2009).
   Web of Science ®Google Scholar
• Tosoni A , FranceschiE , ErmaniMet al. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J. Neurooncol.89(2), 179–185 (2008).
   PubMed Web of Science ®Google Scholar
• Gatto L , FranceschiE , DiNunno Vet al. Liquid biopsy in glioblastoma management: from current research to future perspectives. Oncologist26(10), 865–878 (2021).
   PubMed Web of Science ®Google Scholar
• Weller M , LeRhun E , PreusserM , TonnJC , RothP. How we treat glioblastoma. ESMO Open4(Suppl. 2), e000520 (2019)
   PubMedGoogle Scholar
• Weller M , vanden Bent M , TonnJCet al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol.18(6), 315–329 (2017).
   PubMed Web of Science ®Google Scholar
• Weller M , LeRhun E. How did lomustine become standard of care in recurrent glioblastoma?Cancer Treat. Rev.87, 102029 (2020).
   PubMed Web of Science ®Google Scholar
• Le Rhun E , PreusserM , RothPet al. Molecular targeted therapy of glioblastoma. Cancer Treat. Rev.80, 101896 (2019).
   PubMed Web of Science ®Google Scholar
• Stupp R , MasonWP , vanden Bent MJet al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Howitt BE , ShuklaSA , ShollLMet al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol.1(9), 1319–1323 (2015).
   PubMed Web of Science ®Google Scholar
• Galuppini F , DalPozzo CA , DeckertJ , LoupakisF , FassanM , BaffaR. Tumor mutation burden: from comprehensive mutational screening to the clinic. Cancer Cell Int.19, 209 (2019).
   PubMed Web of Science ®Google Scholar
• Hodges TR , OttM , XiuJet al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol.19(8), 47–57 (2017).
   Web of Science ®Google Scholar
• Dolcetti R , VielA , DoglioniCet al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am. J. Pathol.154(6), 1805–1813 (1999).
   PubMed Web of Science ®Google Scholar
• Pal T , Permuth-WeyJ , SellersTA. A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer. Cancer113(4), 733–472 (2008).
   PubMed Web of Science ®Google Scholar
• McCord M , SteffensA , JavierRet al. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas. Acta Neuropathol. Commun.8(1), 15 (2020).
   PubMed Web of Science ®Google Scholar
• Lombardi G , BarresiV , IndraccoloSet al. Pembrolizumab activity in recurrent high-grade gliomas with partial or complete loss of mismatch repair protein expression: a monocentric, observational and prospective pilot study. Cancers (Basel)12(8), 2283 (2020).
   PubMed Web of Science ®Google Scholar
• Preston BD , AlbertsonTM , HerrAJ. DNA replication fidelity and cancer. Semin. Cancer Biol.20(5), 281–293 (2010).
   PubMed Web of Science ®Google Scholar
• Wang F , ZhaoQ , WangYNet al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol.5(10), 1504–1506 (2019).
   PubMed Web of Science ®Google Scholar
• Rayner E , van GoolIC , PallesCet al. A panoply of errors: polymerase proofreading domain mutations in cancer. Nat. Rev. Cancer16(2), 71–81 (2016).
   PubMed Web of Science ®Google Scholar
• Palles C , CazierJB , HowarthKMet al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet.45(2), 136–144 (2013).
   PubMed Web of Science ®Google Scholar
• Li HD , CuevasI , ZhangMet al. Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load. J. Clin. Invest.128(9), 4179–4191 (2018).
   PubMed Web of Science ®Google Scholar
• Scheel AH , AnsénS , SchultheisAMet al. PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations. Oncoimmunology5(5), e1131379 (2016).
   PubMed Web of Science ®Google Scholar
• Gibney GT , WeinerLM , AtkinsMB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol.17(12), 542–551 (2016).
   PubMed Web of Science ®Google Scholar
• Chalmers ZR , ConnellyCF , FabrizioDet al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med.9(1), 34 (2017).
   PubMed Web of Science ®Google Scholar
• Schumacher TN , SchreiberRD. Neoantigens in cancer immunotherapy. Science348(6230), 69–74 (2015).
   PubMed Web of Science ®Google Scholar
• Chabanon RM , PedreroM , LefebvreCet al. Mutational landscape and sensitivity to immune checkpoint blockers. Clin. Cancer Res.22(17), 4309–4321 (2016).
   PubMed Web of Science ®Google Scholar
• Campbell BB , LightN , FabrizioDet al. Comprehensive analysis of hypermutation in human cancer. Cell171(5), 1042–1056 (2017).
   PubMed Web of Science ®Google Scholar
• Hellmann MD , CiuleanuTE , PluzanskiAet al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med.378(22), 2093–2104 (2018).
   PubMed Web of Science ®Google Scholar
• Rosenberg JE , Hoffman-CensitsJ , PowlesTet al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet387(10031), 1909–1920 (2016).
   PubMed Web of Science ®Google Scholar
• Le DT , UramJN , WangHet al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med.372(26), 2509–2520 (2015).
   PubMed Web of Science ®Google Scholar
• ME IJ , Sanz-PamplonaR , HermitteFet al. Colorectal cancer: a paradigmatic model for cancer immunology and immunotherapy. Mol. Aspects Med.69, 123–129 (2019).
   PubMed Web of Science ®Google Scholar
• Mehnert JM , PandaA , ZhongHet al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J. Clin. Invest.126(6), 2334–2340 (2016).
   PubMed Web of Science ®Google Scholar
• Caccese M , IusT , SimonelliMet al. Mismatch-repair protein expression in high-grade gliomas: a large retrospective multicenter study. Int. J. Mol. Sci.21(18), 6716 (2020).
   PubMed Web of Science ®Google Scholar
• Touat M , LiYY , BoyntonANet al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature580(7804), 517–523 (2020).
   PubMed Web of Science ®Google Scholar
• Wang J , CazzatoE , LadewigEet al. Clonal evolution of glioblastoma under therapy. Nat. Genet.48(7), 768–776 (2016).
   PubMed Web of Science ®Google Scholar
• Barthel FP , JohnsonKC , VarnFSet al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature576(7785), 112–120 (2019).
   PubMed Web of Science ®Google Scholar
• Hunter C , SmithR , CahillDPet al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res.66(8), 3987–3991 (2006).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network . Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature455, 1061–1068 (2008).
   PubMed Web of Science ®Google Scholar
• Marabelle A , LeDT , AsciertoPAet al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol.38(1), 1–10 (2020).
   PubMed Web of Science ®Google Scholar
• Bersanelli M . Tumour mutational burden as a driver for treatment choice in resistant tumours (and beyond). Lancet Oncol.21(10), 1255–1257 (2020).
   PubMed Web of Science ®Google Scholar
• Bouffet E , LaroucheV , CampbellBBet al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol.34(19), 2206–2211 (2016).
   PubMed Web of Science ®Google Scholar
• Johanns TM , MillerCA , DorwardIGet al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov.6(11), 1230–1236 (2016).
   PubMed Web of Science ®Google Scholar
• Ahmad H , FadulCE , SchiffDet al. Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomas. Neurooncol. Pract.6(6), 424–427 (2019).
   PubMed Web of Science ®Google Scholar
• Choi S , YuY , GrimmerMRet al. Temozolomide-associated hypermutation in gliomas. Neuro Oncol.20(10), 1300–1399 (2018).
   PubMed Web of Science ®Google Scholar
• Di Nunno V , FranceschiE , GattoLet al. Predictive markers of immune response in glioblastoma: hopes and facts. Future Oncol.16(15), 1053–1063 (2020).
   PubMed Web of Science ®Google Scholar
• Raimondi A , SepeP , ZattarinEet al. Predictive biomarkers of response to immunotherapy in metastatic renal cell cancer. Front. Oncol.10, 1644 (2020).
   PubMed Web of Science ®Google Scholar
• Herbst RS , SoriaJC , KowanetzMet al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature515(7528), 563–567 (2014).
   PubMed Web of Science ®Google Scholar
• Gandini S , MassiD , MandalàM. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol.100, 88–98 (2016).
   PubMed Web of Science ®Google Scholar
• McGranahan N , FurnessAJ , RosenthalRet al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science351(6280), 1463–1469 (2016).
   PubMed Web of Science ®Google Scholar
• Goodman AM , KatoS , BazhenovaLet al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther.16(11), 2598–2608 (2017).
   PubMed Web of Science ®Google Scholar
• Zehir A , BenayedR , ShahRHet al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med.23(6), 703–713 (2017).
   PubMed Web of Science ®Google Scholar
• Johnson A , SeversonE , GayLet al. Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist22(12), 1478–1490 (2017).
   PubMed Web of Science ®Google Scholar
• Brat DJ , VerhaakRG , AldapeKDet al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med.372(26), 2481–2498 (2015).
   PubMed Web of Science ®Google Scholar
• Wang J , CazzatoE , LadewigEet al. Clonal evolution of glioblastoma under therapy. Nat. Genet.48(7), 768–776 (2016).
   PubMed Web of Science ®Google Scholar
• Kamiya-Matsuoka C , MetrusN , WeathersS-Pet al. Is immuno-oncology therapy effective in hypermutator glioblastomas with somatic or germline mutations? Ann. Oncol. 30, v144 (2019).
   Web of Science ®Google Scholar
• Sa JK , ChoiSW , ZhaoJet al. Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations. Int. J. Cancer144(12), 3023–3030 (2019).
   PubMed Web of Science ®Google Scholar
• Loveless A . Possible relevance of O-6 alkylation of deoxyguanosine to the mutagenicity and carcinogenicity of nitrosamines and nitrosamides. Nature223(5202), 206–207 (1969).
   PubMed Web of Science ®Google Scholar
• Bodell WJ , GaikwadNW , MillerD , BergerMS. Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric brain tumors. Cancer Epidemiol. Biomarkers Prev.12(6), 545–551 (2003).
   PubMed Web of Science ®Google Scholar
• Kaina B , ChristmannM , NaumannS , RoosWP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst.)6(8), 1079–1099 (2007).
   PubMed Web of Science ®Google Scholar
• Esteller M , Garcia-FoncillasJ , AndionEet al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med.343(19), 1350–1354 (2000).
   PubMed Web of Science ®Google Scholar
• Hegi ME , DiserensAC , GorliaTet al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Chien CH , HsuehWT , ChuangJY , ChangKY. Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma. J. Biomed. Sci.28(1), 8 (2021).
   PubMed Web of Science ®Google Scholar
• Johnson BE , MazorT , HongCet al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science343(6167), 189–193 (2014).
   PubMed Web of Science ®Google Scholar
• J. Klempner S , HendifarA , WatersKM. Exploiting temozolomide-induced hypermutation with pembrolizumab in a refractory high-grade neuroendocrine neoplasm: a proof-of-concept case. JCO Precis. Oncol.4, 614–619 (2020).
   PubMed Web of Science ®Google Scholar
• Wu W , KlockowJL , ZhangMet al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol. Res.171, 105780 (2021)
   PubMed Web of Science ®Google Scholar
• McFaline-Figueroa JL , BraunCJ , StanciuMet al. Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide. Cancer Res.75(15), 3127–3138 (2015).
   PubMed Web of Science ®Google Scholar
• Cahill DP , LevineKK , BetenskyRAet al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin. Cancer Res.3(7), 2038–2045 (2007).
   Google Scholar
• Kim J , LeeIH , ChoHJet al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell28(3), 318–328 (2015).
   PubMed Web of Science ®Google Scholar
• Tomczak K , CzerwińskaP , WiznerowiczM. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp. Oncol. (Pozn.)9, 68–77 (2015).
   Google Scholar
• Johnson BE , MazorT , HongCet al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science343(6167), 189–193 (2014).
   PubMed Web of Science ®Google Scholar
• Alexandrov LB , Nik-ZainalS , WedgeDCet al. Signatures of mutational processes in human cancer. Nature500(7463), 415–421 (2013).
   PubMed Web of Science ®Google Scholar
• Daniel P , SabriS , ChaddadAet al. Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities. Front. Oncol.9, 41 (2019).
   PubMed Web of Science ®Google Scholar
• Indraccolo S , LombardiG , FassanMet al. Genetic, epigenetic, and immunologic profiling of MMR-deficient relapsed glioblastoma. Clin. Cancer Res.25(6), 1828–1837 (2019).
   PubMed Web of Science ®Google Scholar
• Yip S , MiaoJ , CahillDPet al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin. Cancer Res.15(14), 4622–4629 (2009).
   PubMed Web of Science ®Google Scholar
• Felsberg J , ThonN , EigenbrodSet al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int. J. Cancer129(3), 659–670 (2011).
   PubMed Web of Science ®Google Scholar
• van Thuijl HF , MazorT , JohnsonBEet al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol.129(4), 597–607 (2015).
   PubMed Web of Science ®Google Scholar
• Ricard D , KaloshiG , Amiel-BenouaichAet al. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann. Neurol.61(5), 484–490 (2007).
   PubMed Web of Science ®Google Scholar
• Izquierdo C , AlentornA , IdbaihAet al. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. J. Neurooncol.136(3), 533–539 (2018).
   PubMed Web of Science ®Google Scholar
• Tang L , DengL , BaiHXet al. Reduced expression of DNA repair genes and chemosensitivity in 1p19q codeleted lower-grade gliomas. J. Neurooncol.139(3), 563–371 (2018).
   PubMed Web of Science ®Google Scholar
• Sun X , TurcanS. From laboratory studies to clinical trials: temozolomide use in IDH-mutant gliomas. Cells10(5), 1225 (2021).
   PubMed Web of Science ®Google Scholar
• Jonsson P , LinAL , YoungRJet al. Genomic correlates of disease progression and treatment response in prospectively characterized gliomas. Clin. Cancer Res.25(18), 5537–5547 (2019).
   PubMed Web of Science ®Google Scholar
• Caccese M , IusT , SimonelliMet al. Mismatch-repair protein expression in high-grade gliomas: a large retrospective multicenter study. Int. J. Mol. Sci.21(18), 6716 (2020).
   PubMed Web of Science ®Google Scholar
• Yu Y , Villanueva-MeyerJ , GrimmerMRet al. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol.23(11), 1872–1884 (2021).
   PubMed Web of Science ®Google Scholar
• Le DT , UramJN , WangHet al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med.372(26), 2509–2520 (2015).
   PubMed Web of Science ®Google Scholar
• Snyder A , MakarovV , MerghoubTet al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med.371(23), 2189–2199 (2014).
   PubMed Web of Science ®Google Scholar
• Carrato C , SanzC , Muñoz-MármolAMet al. The challenge of diagnosing constitutional mismatch repair deficiency syndrome in brain malignancies from young individuals. Int. J. Mol. Sci.22(9), 4629 (2021).
   PubMed Web of Science ®Google Scholar
• Andrianova MA , ChetanGK , SibinMKet al. Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours. J. Pathol.243(3), 331–341 (2017).
   PubMed Web of Science ®Google Scholar
• Aslan K , TurcoV , BlobnerJet al. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nat. Commun.11(1), 931 (2020).
   PubMed Web of Science ®Google Scholar
• Wang Q , HuB , HuXet al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell32(1), 42–56 (2017).
   PubMed Web of Science ®Google Scholar
• De Henau O , RauschM , WinklerDet al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature539(7629), 443–447 (2016).
   PubMed Web of Science ®Google Scholar
• Gatto L , NunnoVD , FranceschiEet al. Chimeric antigen receptor macrophage for glioblastoma immunotherapy: the way forward. Immunotherapy13(11), 879–883 (2021).
   PubMed Web of Science ®Google Scholar
• Rosenthal R , CadieuxEL , SalgadoRet al. Neoantigen-directed immune escape in lung cancer evolution. Nature567(7749), 479–485 (2019).
   PubMed Web of Science ®Google Scholar
• Herrlinger U , TzaridisT , MackFet al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet393(10172), 67 (2019).
   Web of Science ®Google Scholar
• Germano G , LambaS , RospoGet al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature552(7683), 116–120 (2017).
   PubMed Web of Science ®Google Scholar
• Mo F , PellerinoA , SoffiettiR , RudàR. Blood–brain barrier in brain tumors: biology and clinical relevance. Int. J. Mol. Sci.22(23), 12654 (2021).
   PubMed Web of Science ®Google Scholar
• Daneman R , ZhouL , AgalliuD , CahoyJD , KaushalA , BarresBA. The mouse blood-brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. PLoS One5(10), 13741 (2010).
   Web of Science ®Google Scholar
• Desland FA , HormigoA. The CNS and the brain tumor microenvironment: implications for glioblastoma immunotherapy. Int. J. Mol. Sci.21(19), 7358 (2020).
   PubMed Web of Science ®Google Scholar
• Bechmann I , MorG , NilsenJ , ElizaM , NitschR , NaftolinF. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia27(1), 62–74 (1999).
   PubMed Web of Science ®Google Scholar
• Pittet CL , NewcombeJ , PratA , ArbourN. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J. Neuroinflammation8, 155 (2011).
   PubMed Web of Science ®Google Scholar
• Mazanet MM , HughesCC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J. Immunol.69(7), 3581–3588 (2002).
   Google Scholar
• Wherry EJ . T cell exhaustion. Nat. Immunol.12(6), 492–499 (2011).
   PubMed Web of Science ®Google Scholar
• Wherry EJ , KurachiM. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol.15(8), 486–499 (2015).
   PubMed Web of Science ®Google Scholar
• McGrail DJ , PiliéPG , RashidNUet al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol.32(5), 661–672 (2021).
   PubMed Web of Science ®Google Scholar
• Agrawal NS , MillerRJr , LalRet al. Current studies of immunotherapy on glioblastoma. J. Neurol. Neurosurg.1(1), 21000104 (2014).
   PubMedGoogle Scholar
• Hegde PS , KaranikasV , EversS. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res.22(8), 1865–1874 (2016).
   PubMed Web of Science ®Google Scholar
• Singh K , HotchkissKM , PatelKKet al. Enhancing T cell chemotaxis and infiltration in glioblastoma. Cancers (Basel)13(21), 5367 (2021).
   PubMed Web of Science ®Google Scholar
• Hourani T , HoldenJA , LiW , LenzoJC , HadjigolS , O’Brien-SimpsonNM. Tumor associated macrophages: origin, recruitment, phenotypic diversity, and targeting. Front. Oncol.11, 788365 (2021).
   PubMed Web of Science ®Google Scholar
• Mantovani A , MarchesiF , MalesciA , LaghiL , AllavenaP. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol.14(7), 399–416 (2017).
   PubMed Web of Science ®Google Scholar
• Zhou J , TangZ , GaoS , LiC , FengY , ZhouX. Tumor-associated macrophages: recent insights and therapies. Front. Oncol.10, 188 (2020).
   PubMed Web of Science ®Google Scholar
• Samstein RM , LeeCH , ShoushtariANet al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet.51(2), 202–625 (2019).
   PubMed Web of Science ®Google Scholar